News

The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe

At ARVO 2025, in Salt Lake City, Utah, Emma Lessieur-Contreras, MD, PhD, talked about her poster on retina extracellular vesicles, and the role that they play on diabetic retinopathy.

Study reveals faricimab effectively treats diabetic macular edema in underrepresented minorities, showing significant visual acuity improvements and safety across diverse patient populations.

Deep Parikh, MD, sat down with Emily Kaiser Maharjan from Optometry Times to talk about his presentation at Collaborative Care Symposium on advanced treatments in neovascular retinal disease.

At ARVO 2025, in Salt Lake City, Utah, Carly Lam, PhD, MSc, and Tsz Wing Leung, PhD talked about the evaluation of the visual performance of 2 modified DIMS spectacle lens designs.

Investigators were surprised by the outcome of a comparison between the Eyhance and enVista IOLs in low-light conditions.

Sharon Fekrat, MD, FACS, FASRS, highlights the critical importance of networking and collaboration in the medical field, particularly in ophthalmology.

Lori Wright, JD, sat down to talk about a discussion at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.

The Optegra platform currently operates in the Czech Republic, the Netherlands, Poland, Slovakia and the United Kingdom

Early improvements in OSDI scores and tear osmolarity reinforce lifitegrast’s role in managing inflammation-driven dry eye disease.

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg versus 2 mg during the matched dosing phase, and outcomes of shortened, maintained, or extended dosing intervals

Ophthalmologist Dilraj Grewal explores cutting-edge clinical trials for uveitis treatment, highlighting new targeted therapies that aim to control inflammation and macular edema with fewer steroid-related side effects.

Dilraj S. Grewal, MD, FASRS, provides an in-depth overview of the current state of research and treatment innovations.

New clinical guidance for anterior and posterior uveitis was published by a research team from the University of Bristol.

Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and future directions in ophthalmology.

New analysis reveals the ellipsoidal zone's role in predicting geographic atrophy progression, enabling timely interventions to protect photoreceptors.

Lysine, proline and arginine levels progressively increased from non-proliferative DR to proliferative DR stages

This partnership aims to address care gaps by identifying untreated and undertreated patients at scale.

Sunir Garg, MD, discusses a challenge in ophthalmological procedures: patient discomfort during intravitreal injections caused by povidone iodine.

Lexitas Pharma Services' CMO discusses groundbreaking ophthalmology conference, emphasizing innovative clinical trials, emerging treatments for eye diseases, and the potential for transformative patient care strategies.

Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.

A conversation with David S. Friedman, MD, PhD, on treating uncontrolled open-angle glaucoma in patients with limited options

Following his keynote address at Controversies in Modern Eye Care, Dr. Maloney said he will be leaving his surgical practice and returning to research.

The investigators described the CASIA2 (Tomey Corporation) instrument, which is a new AS-OCT device with a swept-source laser wavelength of 1,310 nm that can scan at a speed of 50,000 A-scan/second.

New clinical guidance for anterior and posterior uveitis was published by a research team from the University of Bristol